{
  "source": "PA-Med-Nec-Inbrija.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2164-8\nProgram Prior Authorization/Medical Necessity\nMedication Inbrija® (levodopa inhalation powder)\nP&T Approval Date 5/2019, 7/2019, 7/2020, 12/2020, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nInbrija® (levodopa inhalation powder) is an aromatic amino acid indicated for the intermittent\ntreatment of OFF episodes in patients with Parkinson’s disease treated with\ncarbidopa/levodopa.\nInbrija should only be administered with the Inbrija inhaler.\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Inbrija will be approved based on all of the following criteria:\na. Diagnosis of Parkinson’s disease\n-AND-\nb. Inbrija will be used as intermittent treatment for OFF episodes1\n-AND-\nc. Prescribed by or in consultation with a neurologist or specialist in the treatment of\nParkinson’s disease\n-AND-\nd. Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and\nwill continue receiving treatment with a carbidopa/levodopa-containing medication while\non therapy\n-AND-\ne. Patient continues to experience ≥ 2 hours of OFF time per day despite optimal\nmanagement of carbidopa-levodopa therapy including both of the following:\n(1) Taking carbidopa/levodopa on an empty stomach or at least one half-hour or more\nbefore or one hour after a meal or avoidance of high protein diet\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Dose and dosing interval optimization\n-AND-\nf. History of failure, contraindication, or intolerance to two anti-Parkinson’s disease\ntherapy from the following adjunctive pharmacotherapy classes (trial must be from two\ndifferent classes):\n(1) Dopamine agonists (e.g., pramipexole, ropinirole)\n(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)\n(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)\nAuthorization will be issued for 12 months.\n",
    " ropinirole)\n(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)\n(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Inbrija will be approved based on the following criterion:\na. Documentation of positive clinical response to Inbrija therapy\n-AND-\nb. Patient will continue to receive treatment with a carbidopa/levodopa-containing\nmedication\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Inbrija [package insert]. Pearl River, NY: Acorda Therapeutics, Inc.; December 2022.\n2. LeWitt P, Hauser R, Pahwa R et al. Safety and efficacy of CVT-301 (levodopa inhalation\npowder) on motor function during off periods in patients with Parkinson's disease: a\nrandomised, double-blind, placebo-controlled phase 3 trial. The Lancet Neurology.\n2019;18(2):145-154.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3. Tarsy D. UpToDate. Medical management of motor Fluctuations and Dyskinesia in\nParkinson Disease. 2024 Sep. 23. Accessed December 20, 2024.\nProgram Prior Authorization/Medical Necessity - Inbrija® (levodopa inhalation\npowder)\nChange Control\n5/2019 New program\n7/2019 Updated clinical coverage criteria regarding prior anti-Parkinson’s\ntherapies.\n7/2020 Annual review. No changes to coverage criteria.\n12/2020 Removed evaluation of underlying lung disease from review criteria.\nUpdated references.\n2/2022 Ann",
    "ding prior anti-Parkinson’s\ntherapies.\n7/2020 Annual review. No changes to coverage criteria.\n12/2020 Removed evaluation of underlying lung disease from review criteria.\nUpdated references.\n2/2022 Annual review with no change in clinical criteria.\n2/2023 Annual review with no change in clinical criteria. Updated references.\n2/2024 Annual review. Revised initial authorization to 12 months. Updated\nreferences.\n2/2025 Annual review with no change in clinical criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}